Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit for evaluating curative effect after intensive treatment of pulmonary tuberculosis and prognosis and applications thereof

A technology for intensive treatment and tuberculosis, applied in disease diagnosis, biological testing, material inspection products, etc., can solve the problems of treatment evaluation, poor specificity, and long time consumption, and achieve good detection efficiency, high sensitivity and specificity, and simple operation Effect

Active Publication Date: 2018-07-20
李继承
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the sputum smear has the characteristics of low positive rate and poor specificity, and is affected by many factors such as the patient's sputum content and detection technology.
However, the sputum culture method, which is the gold standard for the diagnosis of pulmonary tuberculosis, takes a long time, requiring 2 to 8 weeks of culture time, and the specificity is only 57.8%, which seriously affects the timely adjustment of the treatment plan.
And some patients have the characteristics of no sputum, less sputum, etc., and the treatment evaluation cannot be carried out by sputum examination.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for evaluating curative effect after intensive treatment of pulmonary tuberculosis and prognosis and applications thereof
  • Kit for evaluating curative effect after intensive treatment of pulmonary tuberculosis and prognosis and applications thereof
  • Kit for evaluating curative effect after intensive treatment of pulmonary tuberculosis and prognosis and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Embodiment 1: Composition of curative effect evaluation and prognosis evaluation kit after intensive treatment of pulmonary tuberculosis

[0054] In this embodiment, the curative effect evaluation and prognosis evaluation kit after intensive treatment of pulmonary tuberculosis includes a microtiter plate, protein standard composition and biotin-labeled antibody composition, sample and antibody diluent, detergent, horseradish Peroxidase-labeled avidin, chromogenic substrate solution, stop solution and microtiter plate attachment, specifically:

[0055] (1) The enzyme plate includes: an enzyme plate coated with an anti-ANGT antibody, purchased from ray biotech company; an enzyme plate coated with an anti-CO7 antibody, an enzyme plate coated with an anti-PLMN antibody, purchased from From abcam company; coated with anti-APOC2 antibody microtiter plate, purchased from abnova company.

[0056] (2) The protein standard composition includes: ANGT, CO7, PLMN and APOC2 protein ...

Embodiment 2

[0069] Example 2: Establishment of the Logistic stepwise regression model of the efficacy evaluation and prognosis evaluation kit after intensive treatment of pulmonary tuberculosis

[0070] The curative effect evaluation and prognosis evaluation kits after intensive treatment of tuberculosis were used to detect the protein levels of ANGT, CO7, PLMN and APOC2 in the serum of healthy controls, newly treated tuberculosis patients, and tuberculosis patients after intensive treatment.

[0071] (1) Serum sample collection:

[0072] According to the diagnostic criteria of tuberculosis issued by the Ministry of Health of China, 48 cases of tuberculosis patients who were not drug-treated at the beginning of treatment, 81 cases of tuberculosis patients after intensive treatment, and 40 cases of healthy controls were collected. The subjects were excluded from tumors, extrapulmonary tuberculosis, diabetes, hepatitis B, AIDS, non-tuberculous mycobacteria, drug-resistant tuberculosis and o...

Embodiment 3

[0094] Example 3: Verification and application of the detection effect of the curative effect evaluation and prognosis evaluation kit after intensive treatment of pulmonary tuberculosis

[0095] Holdout verification: Serum samples were taken from healthy controls, newly treated pulmonary tuberculosis patients, and pulmonary tuberculosis patients after intensive treatment. The sample collection and dilution methods were the same as those described in Example 2.

[0096] Add the diluted sample to be tested into four kinds of enzyme-labeled plates coated with anti-ANGT antibody, CO7 antibody, PLMN antibody, and APOC2 antibody, affix the enzyme-labeled plate, and incubate at room temperature for 1-2.5 hours.

[0097] Discard the waste liquid, pat dry the microtiter plate, and wash 4 to 5 times with detergent. And add the corresponding freshly prepared diluted biotin-labeled antibody to each reaction well, affix the microplate plate, and incubate at room temperature for 1 hour.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
quality scoreaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a kit for evaluating the curative effect after an intensive treatment of pulmonary tuberculosis and prognosis and applications thereof. The kit comprises ELISA plates, a protein standard composition, and a biotin labeled antibody composition. There are four ELISA plates, which respectively comprise an anti-ANGT antibody, an anti-CO7 antibody, an anti-PLMN antibody, and an anti-APOC2 antibody. The protein standard composition comprises ANGT, CO7, PLMN, and APOC2 protein standards. The biotin labeled antibody composition comprises biotin labeled anti-ANGT antibody, biotinlabeled anti-CO7 antibody, biotin labeled anti-PLMN antibody, and biotin labeled anti-APOC2 antibody. The AUC value of the kit for evaluating the curative effect of the intensive treatment of pulmonary tuberculosis is 0.779; the AUC value of the kit for evaluating prognosis of the intensive treatment of pulmonary tuberculosis is 0.837; the prognosis accuracy reaches 84.62%; the accuracy is high,curative effect and prognosis of the intensive treatment of pulmonary tuberculosis can be evaluated by the kit, and a novel evaluation method is provided for the treatment of pulmonary tuberculosis.

Description

technical field [0001] The invention belongs to the technical field of disease curative effect evaluation and prognosis evaluation, in particular to a kit for curative effect evaluation and prognosis evaluation after intensive treatment of pulmonary tuberculosis and its application. Background technique [0002] Pulmonary tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis infection. The current conventional treatment for tuberculosis is divided into two months of intensive treatment and four months of consolidation treatment. In the treatment of pulmonary tuberculosis, the rate of negative conversion of sputum bacteria in newly diagnosed smear-positive patients is the core index reflecting the therapeutic effect. For patients after intensive treatment of tuberculosis, the change of sputum bacteria is the most important thing to adjust the treatment plan and completely cure the disease. [0003] At present, only the traditional sputum smear or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68
CPCG01N33/6884G01N2800/12
Inventor 李继承江婷婷陈静
Owner 李继承
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com